Background
The Client is supporting commercialization of an FDA-cleared AI-enabled diagnostic technology / digital biomarker with an established clinical evidence base. The central question is no longer simply whether the technology works. The current challenge is how the technology can transition from a sponsor-supported research and evidence-generation model into a sustainable U.S. reimbursement and commercialization model.
Primary Question
What is the most viable U.S. reimbursement and commercialization pathway for the technology, and what would need to be true clinically, economically, and operationally for that pathway to succeed?
Proposed Scope
The proposed work is organized around five related questions. The intent is to give the team enough structure to react to what is in scope, what is already known internally, and where deeper analysis may or may not be necessary.
1. Reimbursement Pathway Assessment
Assess whether existing U.S. reimbursement mechanisms could support the technology, including potentially relevant coding, coverage, and payment pathways.
Evaluate whether the technology could fit within, attach to, or be bundled into an existing reimbursement mechanism versus requiring a modified or new mechanism.
Clarify the strategic implications of each path, including likely evidence expectations, timing, feasibility, and dependencies.
Identify circumstances in which traditional reimbursement may not be the most practical initial route and alternative funding or contracting structures should be considered.
2. Economic & Stakeholder Incentive Analysis
Identify which stakeholders receive the greatest clinical, operational, or financial benefit from earlier or more precise identification of the relevant clinical condition.
Assess the relative incentives of commercial payers, Medicare, providers, health systems, integrated payer-provider organizations, employers, and other potential stakeholders.
Evaluate where the economic value of earlier or improved diagnosis actually accrues, including whether downstream treatment or care costs could weaken the payer value proposition in the near term.
Determine which stakeholder groups may have sufficient incentive to pay for, adopt, sponsor, or pilot the technology.
3. Evidence Gap Review
Review the clinical, outcomes, workflow, and commercialization evidence already available from completed and ongoing work.
Assess how the existing evidence aligns with likely payer, provider, and reimbursement decision criteria.
Identify evidence gaps that may materially limit reimbursement or adoption, including clinical utility, economic impact, real-world outcomes, utilization, or implementation evidence.
Distinguish evidence that is essential for the next commercialization step from evidence that may be valuable later but is not immediately required.
4. Commercialization Pathway Options
Translate the reimbursement, stakeholder, and evidence findings into a small number of practical commercialization options.
Define the likely customer, economic buyer, payment mechanism, and role of the technology company under each option.
Consider whether the most realistic initial path is broad reimbursement, narrower adoption within a specific use case or population, direct health-system or payer contracting, a pilot/evidence-development model, or another phased approach.
Identify the tradeoffs among speed to market, evidence burden, scalability, commercial independence, and reimbursement potential.
5. Strategic Recommendation & Roadmap
Synthesize the findings into an initial recommendation regarding the most promising U.S. pathway and the key assumptions that must hold true for that pathway to succeed.
Identify the main strategic choices still requiring Client alignment rather than presenting uncertain assumptions as settled conclusions.
Outline a phased sequence of next steps, including what should be addressed now, what should be validated before additional investment, and what can reasonably wait until later.
Identify where outside specialist support, payer validation, economic modeling, coding expertise, or additional research may be appropriate in a subsequent phase.
Proposed Deliverable
A concise U.S. Reimbursement & Commercialization Strategy that provides enough direction for the Client and technology company to decide what pathway to pursue next. The final output would summarize:
The most promising reimbursement and commercialization pathway(s).
The stakeholder(s) most likely to have a viable reason to pay for or adopt the technology.
Whether an existing reimbursement mechanism appears viable, whether a new or modified mechanism should be explored, or whether an alternative contracting model is preferable.
The evidence already available and the most important remaining evidence gaps.
The major assumptions that still require validation.
A phased set of recommended next steps and decision triggers.
Client Inputs / Existing Work
Akros would seek to leverage, rather than recreate, work already completed by the Client and its technology partner. Relevant inputs may include existing clinical studies, regulatory materials, ongoing study plans, prior workflow or competitive analysis, internal market and claims analyses, and available health-economic work. The exact inputs required would be confirmed during scoping.
Potential Follow-on Work
Depending on the conclusions of the initial strategy work, a subsequent phase could include deeper payer validation, coding strategy, health-economic or budget-impact modeling, pilot design, external stakeholder interviews, or implementation support. These activities would be scoped only after the preferred pathway and evidence needs are clearer.
Timing & Investment
Timing and final investment would be confirmed after alignment with the Client team on the scope, the depth of analysis required, and the extent to which existing internal work can be leveraged. Akros anticipates a phased approach so that the team can review early findings and make explicit go/no-go decisions before committing to deeper or more resource-intensive workstreams.